PQQ (Pyrroloquinoline Quinone)

Pyrroloquinoline quinone is a small redox-active molecule present in fermented foods, kiwi, and green tea. It has never been assigned status as an essential human vitamin, though some researchers in the field have argued it should be, based on the fact that PQQ-deficient diets in animals produce measurable defects.

The mechanistic case rests mainly on one 2010 paper. Chowanadisai and colleagues exposed mouse liver cells to PQQ and found increased mitochondrial DNA content, citrate synthase activity, and cellular respiration, driven by activation of CREB phosphorylation and increased expression of PGC-1alpha, the transcriptional coactivator that functions as a master regulator of mitochondrial biogenesis [1]. This is a real, mechanistically detailed cell-culture finding. It is not a human clinical result, and no independent lab has since published a comparable demonstration of PQQ-driven mitochondrial biogenesis in living human tissue.

On the human side, a randomized, double-blind, placebo-controlled trial in Japanese adults aged 40 to under 80 gave 21.5 mg/day of PQQ disodium salt (branded mnemoPQQ) for 12 weeks and found significant improvements on several Cognitrax subdomains, including verbal memory, reaction time, and cognitive flexibility, compared to placebo [2]. The trial was well-designed on paper: randomized, blinded, with a validated cognitive battery as primary endpoint. It was funded by the manufacturer of the tested ingredient.

What the evidence does not show: nearly every published positive human trial of PQQ has been funded, in whole or part, by one of two companies that manufacture PQQ disodium salt supplements, Mitsubishi Gas Chemical and Ryusendo. A regulatory safety review commissioned for a novel-food application catalogued twelve human clinical studies using doses from 10 to 100 mg/day for three days to 24 weeks, and noted plainly that several of these studies showed no significant effect of PQQ on the outcomes tested [3]. That detail, buried in a safety dossier rather than a marketing page, is a more balanced picture than most consumer-facing PQQ content presents. Separately, a trial in older adults with diagnosed mild cognitive impairment, a harder and more clinically meaningful population than healthy volunteers, found PQQ combined with magnesium did not improve overall cognition on standard dementia scales, apart from one narrow subcategory out of twelve measured.

No self-experimentation program tracked in Blueprint's published supplement stacks has publicly documented PQQ as a standing daily ingredient with a specific verified dose; claims that Bryan Johnson takes PQQ circulate in third-party summaries but are not confirmed on his official product pages, so this entry does not assign him a dose.

Critics of the PQQ evidence base point to the pattern seen across many nutraceutical compounds: a striking, mechanistically clean cell-culture or rodent finding gets followed by a cluster of small, short, industry-funded human trials that report positive results on subjective or composite cognitive measures, while trials in harder clinical populations, like diagnosed cognitive impairment, tend to come up null or marginal.

The honest takeaway: PQQ has a genuinely interesting mitochondrial mechanism demonstrated in mouse liver cells, and a scattered human trial record dominated by manufacturer funding that shows some positive cognitive findings in healthy older adults but not in people with diagnosed cognitive impairment.

Products with this: PQQ